EIF3I
Eukaryotic translation initiation factor 3 subunit I
Also known as: eIF3-beta, eIF3-p36, EIF3I_HUMAN, EIF3S2, TRIP-1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13347
- Gene
- EIF3I
- Ensembl
- ENSG00000084623
- Chromosome
- 1
- Canonical length
- 325 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Cytosol
OverviewNCBI Gene
Contributes to translation initiation factor activity. Involved in translational initiation. Located in extracellular exosome. Part of eukaryotic translation initiation factor 3 complex. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
325 residues, UniProt reviewed canonical sequence.
>Q13347|EIF3I
1 MKPILLQGHE RSITQIKYNR EGDLLFTVAK DPIVNVWYSV NGERLGTYMG HTGAVWCVDA
61 DWDTKHVLTG SADNSCRLWD CETGKQLALL KTNSAVRTCG FDFGGNIIMF STDKQMGYQC
121 FVSFFDLRDP SQIDNNEPYM KIPCNDSKIT SAVWGPLGEC IIAGHESGEL NQYSAKSGEV
181 LVNVKEHSRQ INDIQLSRDM TMFVTASKDN TAKLFDSTTL EHQKTFRTER PVNSAALSPN
241 YDHVVLGGGQ EAMDVTTTST RIGKFEARFF HLAFEEEFGR VKGHFGPINS VAFHPDGKSY
301 SSGGEDGYVR IHYFDPQYFE FEFEALocalizationUniProt · AlphaFold · HPA
Whether an antibody against EIF3I can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.23
- Highest tissue expression
- 251 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 251 nTPM
- tongue: 202 nTPM
- tonsil: 171 nTPM
- ovary: 154 nTPM
- rectum: 149 nTPM
- thymus: 148 nTPM
Single-cell type
- esophageal suprabasal cells: 522 nCPM
- esophageal basal cells: 469 nCPM
- extravillous trophoblasts: 401 nCPM
- syncytiotrophoblasts: 385 nCPM
- migrating cytotrophoblasts: 379 nCPM
- decidual stromal cells: 375 nCPM
Immune cell
- total PBMC: 308 nTPM
- myeloid DC: 246 nTPM
- T-reg: 238 nTPM
- intermediate monocyte: 225 nTPM
- classical monocyte: 204 nTPM
- NK-cell: 195 nTPM
Brain region
- white matter: 71 nTPM
- choroid plexus: 71 nTPM
- cerebellum: 66 nTPM
- thalamus: 61 nTPM
- pons: 60 nTPM
- spinal cord: 59 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.35
- gnomAD pLI
- 0.95
- gnomAD missense Z
- 2.46
- DepMap mean gene effect
- -1.69
- DepMap dependency class
- pan
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cytoplasmic translational initiation
- formation of cytoplasmic translation initiation complex
- translational initiation
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- WD40 repeat
- WD40/YVTN repeat-like-containing domain superfamily
- WD40 repeat, conserved site
- WD40-repeat-containing domain superfamily
- Eukaryotic translation initiation factor 3 subunit I
- EIF3I
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of EIF3I in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads EIF3I as an antibody target. Whether an autoantibody or antibody against EIF3I could matter depends on whether native EIF3I is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
EIF3I is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label EIF3I as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...